Topic: Neuroscience

Researchers from VIB and KU Leuven discovered how Lecanemab, a monoclonal antibody treatment for Alzheimer's disease, removes toxic amyloid plaques. The study found that the Fc fragment of the antibody activates microglia, which then clear these plaques.

Alzheimer's disease is a major health concern worldwide, affecting over 55 million people. It's characterized by the buildup of toxic protein clusters called amyloid plaques in the brain. These plaques damage neurons and eventually lead to dementia. To combat this, researchers have been developing treatments aimed at restoring the immune function of microglia, which naturally gather around these plaques but are unable to remove them effectively.

Lecanemab is one such therapy that targets amyloid-beta plaques and slows disease progression. It has received FDA approval, but side effects have limited its overall benefit. Until now, the exact mode of action of Lecanemab remained unclear.

The team led by Prof. Bart De Strooper demonstrated that the Fc fragment of Lecanemab is essential for activating microglia to clear plaques. They used a specially designed Alzheimer's mouse model that included human microglial cells to closely observe how Lecanemab interacts with human immune cells and promotes plaque clearance.

The researchers found that when the Fc fragment was removed, the antibody no longer had any effect. This suggests that the Fc fragment acts as an anchor that microglia latch onto when they are near plaques, reprogramming them to clear plaques more efficiently.

Why It Matters

Understanding how Lecanemab works is crucial for developing safer and more effective Alzheimer's treatments. As India grapples with its own aging population and rising dementia cases, this research has significant implications for the country's healthcare sector.

Key Facts

• Lecanemab is a monoclonal antibody treatment that targets amyloid-beta plaques in the brain
• The Fc fragment of Lecanemab activates microglia to clear these plaques
• Researchers used a specially designed Alzheimer's mouse model with human microglial cells to study Lecanemab's effects
• The Fc fragment acts as an anchor that microglia latch onto when they are near plaques, reprogramming them to clear plaques more efficiently

Key Terms

Amyloid plaques

Toxic protein clusters in the brain that damage neurons and cause dementia

Implications

Understanding how Lecanemab works is crucial for developing safer and more effective Alzheimer's treatments. As India grapples with its own aging population and rising dementia cases, this research has significant implications for the country's healthcare sector.